5don MSN
Access to potentially life-saving neurosurgical care remains very uneven worldwide, with potentially life-threatening ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
After hours: March 21 at 7:13:50 PM EDT Loading Chart for VRTX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results